However, as subsets of breast cancers do not express FcγRIIIa or indeed any FcγR in the TME (Fig. 1), such patients may require other strategies, such as antibody–drug conjugates, which do not require immune cell engagement. This evidence concerns the gene FCGR2A and breast cancer.